Log in

Relevant bibliographies by topics / Programmed Cell Death 1 Receptor Leukocyte Immunoglobulin-Like Receptor B1

Contents

Journal articles
Dissertations / Theses

Academic literature on the topic 'Programmed Cell Death 1 Receptor Leukocyte Immunoglobulin-Like Receptor B1'

Author: Grafiati

Published: 24 May 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Programmed Cell Death 1 Receptor Leukocyte Immunoglobulin-Like Receptor B1.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Programmed Cell Death 1 Receptor Leukocyte Immunoglobulin-Like Receptor B1"

1

Poggi, Alessandro, Serena Matis, Chiara Rosa Maria Uras, Lizzia Raffaghello, Roberto Benelli, and Maria Raffaella Zocchi. "The Role of LAIR1 as a Regulatory Receptor of Antitumor Immune Cell Responses and Tumor Cell Growth and Expansion." Biomolecules 15, no. 6 (2025): 866. https://doi.org/10.3390/biom15060866.

Full text

Abstract:

It is becoming evident that the therapeutic effect of reawakening the immune response is to limit tumor cell growth and expansion. The use of immune checkpoint inhibitors, like blocking antibodies against programmed cell death receptor (PD) 1 and/or cytotoxic T lymphocyte antigen (CTLA) 4 alone or in combination with other drugs, has led to unexpected positive results in some tumors but not all. Several other molecules inhibiting lymphocyte antitumor effector subsets have been discovered in the last 30 years. Herein, we focus on the leukocyte-associated immunoglobulin (Ig)-like receptor 1 (LAI

APA, Harvard, Vancouver, ISO, and other styles

2

Kalinka, Ewa, Kamila Wojas-Krawczyk, and Paweł Krawczyk. "Double Guard Efficiency and Safety—Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients." Cancers 15, no. 13 (2023): 3499. http://dx.doi.org/10.3390/cancers15133499.

Full text

Abstract:

Immunotherapy is one of the leading systemic therapies in non-small cell cancer (NSCLC) patients, but it is not effective in an important proportion of them due to primary or secondary resistance mechanisms. Clinicians do not have the tools to predict immunotherapy resistance, and thus, many patients still fail initial treatment. One of the scientific concepts to avoid resistance and/or offer the patient effective salvage second-line treatment is the dual immunologic checkpoint blockade. We aimed to review published and available data on combination immunotherapy in terms of mechanisms, effica

APA, Harvard, Vancouver, ISO, and other styles

3

Jones, Des C., Lorraine Irving, Rebecca Dudley, et al. "LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity." Journal for ImmunoTherapy of Cancer 13, no. 4 (2025): e010012. https://doi.org/10.1136/jitc-2024-010012.

Full text

Abstract:

BackgroundImmune checkpoint inhibitors have revolutionized the treatment of solid tumors, enhancing clinical outcomes by releasing T cells from inhibitory effects of receptors like programmed cell death protein 1 (PD-1). Despite these advancements, achieving durable antitumor responses remains challenging, often due to additional immunosuppressive mechanisms within the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) contribute significantly to the immunosuppressive TME and play a pivotal role in shaping T cell-mediated antitumor responses. Leukocyte immunoglobulin-like recept

APA, Harvard, Vancouver, ISO, and other styles

4

Taylor, Matthew H., Aung Naing, John Powderly, et al. "Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors." Journal for ImmunoTherapy of Cancer 12, no. 11 (2024): e010006. http://dx.doi.org/10.1136/jitc-2024-010006.

Full text

Abstract:

PurposeIn this first-in-human dose escalation study, the safety and efficacy of IO-108, a fully human monoclonal antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), was investigated in patients with advanced solid tumors as monotherapy and in combination with pembrolizumab, an anti-programmed cell death protein 1 (PD-1) antibody.MethodsThe study included patients with histologically or cytologically confirmed advanced and relapsed solid tumors, with measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) V.1.1. Patients were treated with escalating doses

APA, Harvard, Vancouver, ISO, and other styles

5

Xian, Miao, Qing Yi, Qiang Wang, et al. "Abstract 364: Targeting LILRB1 to sensitize human myeloma to ferroptosis through disrupting cholesterol homeostasis." Cancer Research 84, no. 6_Supplement (2024): 364. http://dx.doi.org/10.1158/1538-7445.am2024-364.

Full text

Abstract:

Abstract Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled clonal proliferation of plasma cells in the bone marrow (BM). Despite the demonstrated benefits of novel therapies, relapses are frequent, and acquired resistance to MM treatment eventually emerges in most, if not all, patients. MM patients who suffer more aggressive progression usually result in poorer survival. The genes driving such unfavored outcomes in MM have not been fully understood. Therefore, there is an urgent need to identify the genes and mechanisms that contribute to the aggressive behavi

APA, Harvard, Vancouver, ISO, and other styles

6

Samantha, Boever Andrew Chang Kylie Daguio James Keane and Leonard B. Goldstein*. "Low-Dose Radiation Therapy for Painful Osteoarthritis: An Emerging Treatment Modality." World Journal of Health and Medicine 1, no. 3 (2024): 80–86. https://doi.org/10.5281/zenodo.10611600.

Full text

Abstract:

<strong>Abstract</strong> Osteoarthritis is the most common degenerative joint disease worldwide, and its prevalence is steadily rising due to an aging population and increased risk factors such as obesity and sedentary lifestyles. Despite the increase in investigative research on Low-Dose Radiation Therapy (LDRT) occurring in other countries and current clinical use, LDRT is inappreciably used in the United States. Numerous studies published outside the U.S. indicate moderate to long-term pain relief and increased mobility following the treatment of joints affected by osteoarthritis with LDRT

APA, Harvard, Vancouver, ISO, and other styles

7

Aung, Thazin Nwe, Niki Gavrielatou, Ioannis A. Vathiotis, et al. "Quantitative, Spatially Defined Expression of Leukocyte Associated Immunoglobulin-like Receptor (LAIR-1) in Non-Small Cell Lung Cancer." Cancer Research Communications, February 22, 2023. http://dx.doi.org/10.1158/2767-9764.crc-22-0334.

Full text

Abstract:

Abstract Targeting the interaction of Leukocyte Associated Immunoglobulin-like Receptor-1 (LAIR-1) and its ligands has been shown to reinstate anti-tumor immunity. In addition, the introduction of the LAIR-1 decoy protein, LAIR-2, sensitizes previously resistant lung tumors to programmed death-1 (PD-1) blockade, indicating the potential of LAIR-1 as an alternative marker for anti-PD-1 resistance in lung cancer. Here, we assessed LAIR-1 as compared to programmed death-ligand 1 (PD-L1) expression in various tumors, with a focus on non-small cell lung cancer (NSCLC) and its histological subtypes

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Programmed Cell Death 1 Receptor Leukocyte Immunoglobulin-Like Receptor B1"

1

Dumont, Clément. "Importance des lymphocytes T effecteurs exprimant ILT2 dans les cancers urologiques traités par immunothérapie." Electronic Thesis or Diss., Université Paris Cité, 2024. http://www.theses.fr/2024UNIP5267.

Full text

Abstract:

L'immunothérapie par inhibiteurs des points de contrôle immunitaires (ICI) fonctionne à travers l'expansion de lymphocytes T CD8+ effecteurs antitumoraux à partir de précurseurs "exhausted" exprimant le récepteur inhibiteur PD-1. Elle est désormais incontournable dans le traitement des carcinomes rénaux à cellules claires (CRcc) et urothéliaux (CU). Nous avons préalablement démontré que le microenvironnement tumoral du CRcc chez l'homme comprend une populations de lymphocytes T CD8+ effecteurs exprimant le récepteur inhibiteur ILT2 (LILRB1) mais pas PD-1, hautement cytotoxiques mais pouvant êt

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!